Proceedings of the Texas A&M Medical Student Grand Rounds

IgG and IgA Antibody Transmission After COVID-19: Comparing Infection, Vaccination, and Breastfeeding

June 12, 2022 Caroline Keefer

Caroline Keefer

Introduction: SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. As of May 9, 2022, more than 500 million people have been infected, and more than six million people have died.1 In this study, IgG and IgA transmission was investigated, studying its role in conferring immunity to fetuses and infants after natural infection, vaccination, and during breastfeeding. One of the main concerns at the beginning of the pandemic was how pregnant people and fetuses would be affected, so this research topic is significant. The purpose of this study was to determine what the safest and most efficient mode of antibody transfer was for fetuses and infants, since they cannot currently be vaccinated against SARS-CoV-2. Risks of COVID-19 disease during pregnancy include greater instances of stillbirth, pre-eclampsia, placental inflammation, preterm delivery, and maternal and neonatal mortality.2  Methods: Antibodies are commonly passed from mother to fetus via endosomal transmission across the placenta,3 so it was important to compare cord blood samples to their maternal counterpart.4,5 Researchers analyzed blood samples in maternal-fetal and maternal-infant dyads before and after infection, vaccination, and during breastfeeding.4,6 Enzyme-linked immunosorbent assay (ELISA) was utilized to analyze antibody titers.4 Researchers also investigated whether COVID-19 is transferred vertically by testing cord blood and breastmilk for SARS-CoV-2.2,5 Results: Vertical transmission of SARS-CoV-2 is rare, and this was determined by analyzing cord blood samples.5 After infection, IgG was elevated in dyad samples, with statically significant p-values for levels in maternal blood and cord blood samples.5 However, some researchers found compromised antibody transfer during infection.3 Vaccination also leads to elevated levels of anti-spike protein IgG antibodies in maternal and cord blood, with p-values less than 0.001.4 Mothers who were vaccinated with an mRNA vaccine between 20 and 32 weeks of pregnancy showed higher levels of IgG in their blood post-vaccination compared to naturally infected mothers.4 After mRNA vaccination, breastmilk elicited IgG and IgA neutralization capabilities.6 Researchers also found that at six months of age, infants of vaccinated mothers had higher levels of anti-spike protein IgG in their blood.4 Conclusion: SARS-CoV-2 infection during pregnancy will provide IgG protection, but not as effectively as vaccination.4 Due to the risks that come with natural infection during pregnancy,2 vaccination is the safer option for pregnant people to confer immunity to their child. It can also be concluded that it is beneficial to breastfeed after COVID-19 vaccination, as IgG and IgA are transferred via breastmilk.6

  1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ Accessed May 9, 2022.
  2. Male, V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol22, 277–282 (2022). https://doi.org/10.1038/s41577-022-00703-6
  3. Atyeo C, Pullen KM, Bordt EA, et al. Compromised SARS-CoV-2-specific placental antibody transfer. Cell. 2021;184(3):628-642.e10. doi:10.1016/j.cell.2020.12.027
  4. Shook LL, Atyeo CG, Yonker LM, et al. Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection. JAMA. 2022;327(11):1087–1089. doi:10.1001/jama.2022.1206
  5. Garcia-Flores, V., Romero, R., Xu, Y. et al. Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. Nat Commun 13, 320 (2022). https://doi.org/10.1038/s41467-021-27745-z
  6. Rosenberg-Friedman, M., Kigel, A., Bahar, Y. et al. BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women. Nat Commun 12, 6222 (2021). https://doi.org/10.1038/s41467-021-26507-1
Immunology Microbiology
Previous Post

Effects of Systemic Inflammation and Nitric Oxide Imbalance on Heart Failure with Preserved Ejection Fraction (HFpEF)

Next Post

Prohibitin as a Critical Mediator of Glioblastoma Radioresistance and a Potential Target for Emerging Therapies

Scientific Editors

Steve A. Maxwell

Executive Editor
Tel: 979-436-0804
smaxwell@medicine.tamhsc.edu

Robin Fuchs-Young

Deputy Editor
Tel: 979-845-5109
fuchs-young@medicine.tamhsc.edu
Administrative Editor

Janis Chmiel

Tel: 979-436-0856
chmiel@medicine.tamhsc.edu
Editorial Office
Tel.: 979-845-2726
Fax: 979-847-9481
chmiel@medicine.tamhsc.edu
Archives
  • July 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • May 2025
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • November 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • August 2022
  • June 2022
  • May 2022
  • August 2021
  • July 2021
  • April 2021
  • October 2020
  • August 2020
  • July 2020
  • August 2019
  • July 2019
  • February 2019
  • July 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • January 2017
Proudly powered by WordPress | Theme: Fmi by Forrss.